Protein kinase inhibitors: The tyrosine-specific protein kinases

Pharmacology and Therapeutics

Volumn 77, Issue 2, 1998, Pages 81-114

  Lawrence, David S ^a   Niu, Jinkui ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Anticancer agents; Inhibitors; Signal transduction; Tyrosine specific protein kinases

Indexed keywords

ADENOSINE TRIPHOSPHATE DERIVATIVE; COUMARIN; ERBSTATIN; ISOQUINOLINE DERIVATIVE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUERCETIN; QUINAZOLINE; QUINOXALINE DERIVATIVE;

DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; REVIEW;

ADENOSINE TRIPHOSPHATE; ANIMALS; BINDING SITES; BIOLOGICAL AVAILABILITY; ENZYME INHIBITORS; HUMANS; PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0031887743     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(97)00052-1     Document Type: Review

References (240)

1. Abedi H., Zachary I. Signalling mechanisms in the regulation of vascular cell migration. Cardiovasc. Res. 30:1995;544-556.
2. Agbotounou W. K., Levitzki A., Jacquemin-Sablon A., Pierre J. Effects of tyrphostins on the activated c-Src protein in NIH/3T3 cells. Mol. Pharmacol. 45:1994;922-931. a.
3. Agbotounou W. K., Mousset S., Piperno S., Pierre M., Jacquemin-Sablon A., Pierre J. Activation of the mitogen-activated protein kinase cascade by tyrphostin (RG 50864). Biochem. Pharmacol. 48:1994;505-515. b.
4. F527 in vitro and in intact cells. Eur. J. Pharmacol. 269:1994;1-8. c.
5. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukani Y. Genistein, a specific inhibitor of tyrosine specific protein kinases. J. Biol. Chem. 262:1987;5592-5595.
6. Alexandropoulos K., Cheng G., Baltimore D. Proline-rich sequences that bind to Src homology 3 domains with individual specificities. Proc. Natl. Acad. Sci. USA. 92:1995;3110-3114.
7. Alonso G., Koegl M., Mazurenko N., Courtneidge S. A. Sequence requirements for binding of Src family tyrosine kinases to activated growth factor receptors. J. Biol. Chem. 270:1995;9840-9888.
8. Alvi K. A., Rodriguez J., Diaz M. C., Moretti R., Wilhelm R. S., Lee R. H., Slate D. L., Crews P. Protein tyrosine kinase inhibitory properties of planar polycyclics obtained from the marine sponge Xestospongia cf. Carbonaria and from total synthesis. J. Org. Chem. 58:1993;4871-4880.
9. Anafi M., Gazit A., Gilon C., Ben-Neriah Y., Levitzki A. Selective interactions of transforming and normal Abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J. Biol. Chem. 267:1992;4518-4523.
10. Anafi M., Gazit A., Zehavi A., Ben-Neriah Y., Levitzki A. Tyrphostin-induced inhibition of p210Bcr-Abl tyrosine kinase activity induces K562 to differentiate. Blood. 82:1993;3524-3529.
11. Basu T., Warne P. H., Downward J. Role of Shc in the activation of ras in response to epidermal growth factor and nerve growth factor. Oncogene. 9:1994;3483-3491.
12. Blumberg P. M., Acs G., Acs P., Areces L. B., Kazanietz M. G., Lewin N. E., Szallasi Z. Protein kinase C in cell signaling: strategies for the development of selective inhibitors Agents Actions Suppl. 47:1995;87-100.
13. Bolin D. R., Cottrell J., Garippa R., Michalewsky J., Rinaldi N., Simko B., O'Donnell M. Structure-activity studies on the vasoactive intestinal peptide pharmacophore: 1. Analogs of tyrosine Int. J. Pept. Protein Res. 46:1995;279-289.
14. Bonfini L., Migliaccio E., Pelicci G., Lanfrancone L., Pelicci P. G. Not all Shc's roads lead to Ras. Trends Biochem. Sci. 21:1996;257-261.
15. Boutin J. A. Tyrosine protein kinase inhibition and cancer. Int. J. Biochem. 26:1994;1203-1226.
16. Braun S., Abdel Ghany M., Racker E. A rapid assay for protein kinases phosphorylating small polypeptides and other substrates. Anal. Biochem. 135:1983;369-378.
17. Bridges A. J., Cody D. R., Zhou H., McMichael A., Fry D. W. Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(α-phenethylamino)quinazolines. Bioorg. Med. Chem. 3:1995;1651-1656.
18. Bridges A. J., Zhou H., Cody D. R., Rewcastle G. W., McMichael A., Showalter H. D., Fry D. W., Kraker A. J., Denny W. A. Tyrosine kinase inhibitors 8: An unusually steep structure-activity relationship for analogues of 4-3-bromoanilino-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor J. Med. Chem. 39:1996;267-276.
19. Brunton V. G., Workman P. Cell-signaling targets for antitumour drug development. Cancer Chemother. Pharmacol. 32:1993;1-19.
20. Brunton V. G., Kelland L. R., Lear M. J., Montgomery G. J., Robertson J. H., Robins D. J., Queen J., Workman P. Synthesis and biological evaluation of a series of tyrphostins containing nitrothiophene moieties as possible epidermal growth factor receptor tyrosine kinase inhibitors. Anticancer Drug Des. 11:1996;265-295. a.
21. Brunton V. G., Lear M. J., McKeown P., Robins D. J., Workman P. Synthesis and antiproliferative activity of tyrphostins containing quinoline moieties. Anticancer Drug Des. 11:1996;463-483. b.
22. Buchdunger E., Trinks U., Mett H., Regenass U., Muller M., Meyer T., McGlynn E., Pinna L. A., Traxler P., Lydon N. B. 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity Proc. Natl. Acad. Sci. USA. 91:1994;2334-2338.
23. Buchdunger E., Zimmermann J., Mett H., Meyer T., Müller M., Regenass U., Lydon N. B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA. 92:1995;2558-2562.
24. Buchdunger E., Zimmermann J., Mett H., Meyer T., Müller M., Druker B. J., Lydon N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
25. Bunnell S. C., Henry P. A., Kolluri R., Kirchhausen T., Rickles R. J., Berg L. J. Identification of Itk/Tsk Src homology 3 domain ligands. J. Biol. Chem. 271:1996;25646-25656.
26. Burg D. L., Geahlen R. L. Synthesis and protein tyrosine kinase inhibitory activity of flavonoid analogs. J. Med. Chem. 34:1991;798-806.
27. Burke T. R. Jr. Protein-tyrosine kinases: potential targets for anticancer drug development Stem Cells. 12:1994;1-6.
28. Lck. J. Med. Chem. 36:1993;425-432.
29. Burke T. R. Jr., Smyth M. S., Otaka A., Nomizu M., Roller P. P., Wolf G., Case R., Shoelson S. E. Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors. Biochemistry. 33:1994;6490-6494.
30. Burke T. R. Jr., Barchi J. J. Jr., George C., Wolf G., Shoelson S. E., Yan X. Conformationally constrained phosphotyrosyl mimetics designed as monomeric Src homology 2 domain inhibitors. J. Med. Chem. 38:1995;1386-1396.
31. Burke T. R. Jr., Ye B., Akamatsu M., Ford H. Jr., Yan X., Kole H. K., Wolf G., Shoelson S. E., Roller P. P. 4′-O-[2-(2-Fluoromalonyl)]-L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides J. Med. Chem. 39:1996;1021-1027.
32. Butturini A., Arlinghaus R. B., Gale R. P. BCR/ABL and leukemia. Leuk. Res. 20:1996;523-529.
33. Buzzetti F., Brasca M. G., Crugnola A., Fustinoni S., Longo A., Penco S. Cinnamide analogs as inhibitors of protein tyrosine kinases. Farmaco. 48:1993;615-636.
34. Cance W. G., Liu E. T. Protein kinases in human breast cancer. Breast Cancer Res. Treat. 35:1996;105-114.
35. Cantley L. C., Songyang Z. Specificity in recognition of phosphopeptides by Src-homology 2 domains. J. Cell Sci. Suppl. 18:1994;121-126.
36. Casnellie J. E. Protein kinase inhibitors: probes for the functions of protein phosphorylation Adv. Pharmacol. 22:1992;167-205.
37. Chang C. J., Geahlen R. L. Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents J. Nat. Prod. 55:1992;1529-1560.
38. erbB2 J. Biol. Chem. 271:1996;4974-4977.
39. Cheadle C., Ivashchenko Y., South V., Searfoss G. H., French S., Howk R., Ricca G. A., Jaye M. Identification of a Src SH3 domain binding motif by screening a random phage display library. J. Biol. Chem. 269:1994;24034-24039.
40. Chen H., Boiziau J., Parker F., Maroun R., Tocque B., Roques B. P., Garbay-Jaureguiberry C. Synthesis and structure-activity studies of a series of [(hydroxybenzyl)amino]salicylates as inhibitors of EGF receptor-associated tyrosine kinase activity. J. Med. Chem. 36:1993;4094-4098.
41. Chen H., Boiziau J., Parker F., Mailliet P., Commercon A., Tocque B., Le Pecq J.-B., Roques B-P., Garbay C. Structure-activity relationships in a series of 5-[(2,5-dihydroxybenzyl)amino]salicylate inhibitors of EGF-receptor-associated tyrosine kinase: importance of additional hydrophobic interactions J. Med. Chem. 37:1994;845-859.
42. Chen H., Bashiardes P., Mailliet P., Commercon A., Sounigo F., Boiziau J., Parker F., Tocque B., Roques B. P., Garbay C. Synthesis and biological evaluation of a series of hydroxybenzylphenylamine derivatives as inhibitors of the EGF receptor-associated tyrosine kinase activity. Anticancer Drug Des. 11:1996;49-71.
43. Chen J. L., Proteau P. J., Roberts M. A., Gerwick W. H., Slate D. L., Lee R. H. Structure of malhamensilipin A, an inhibitor of protein tyrosine kinase, from the cultured chrysophyte Poterioochromonas malhamensis. J. Nat. Prod. 57:1994;524-527.
44. Chorvath B., Sedlak J. Protein kinase inhibitors: induction of apoptosis and drug-resistance modulation in neoplastic cell lines Neoplasma. 43:1996;3-9.
45. Cole P. A., Grace M. R., Phillips R. S., Burn P., Walsh C. T. The role of the catalytic base in the protein tyrosine kinase Csk. J. Biol. Chem. 270:1995;22105-22108.
46. Combs A. P., Kapoor T. M., Feng S., Chen J. K., Daudé-Snow L. F., Schreiber S. L. Protein structure-based combinatorial chemistry: discovery of non-peptide binding elements to Src SH3 domain J. Am. Chem. Soc. 118:1996;287-288.
47. Cowburn D., Zheng J., Xu Q., Barany G. Enhanced affinities and specificities of consolidated ligands for the Src homology (SH) 3 and SH2 domains of Abelson protein-tyrosine kinase. J. Biol. Chem. 270:1995;26738-26741.
48. Cushman M., Nagarathnam D., Burg D. L., Geahlen R. L. Synthesis and protein-tyrosine kinase inhibitory activities of flavonoid analogues. J. Med. Chem. 34:1991;798-806. a.
49. lck. J. Nat. Prod. 54:1991;1345-1352. b.
50. Davies L. P., Jamieson D. D., Baird-Lambert J. A., Kazlauskas R. Halogenated pyrrolopyrimidine analogues of adenosine from marine organisms: pharmacological activities and potent inhibition of adenosine kinase Biochem. Pharmacol. 33:1984;347-355.
51. Davies L. P., Baird-Lambert J., Marwood J. F. Studies on several pyrrolo[2,3-d]pyrimidine analogues of adenosine which lack significant agonist activity at A1 and A2 receptors but have potent pharmacological activity in vivo. Biochem. Pharmacol. 35:1986;3021-3029.
52. Delmotte P., Delmotte-Plaquee J. A new antifungal substance of fungal origin. Nature. 171:1953;344.
53. Dobrusin E. M., Fry D. W. Protein tyrosine kinases and cancer. Annu. Rep. Med. Chem. 27:1992;169-178.
54. Dolle R. E., Dunn J. A., Bobko M., Singh B., Kuster J. E., Baizman E., Harris A. L., Sawutz D. G., Miller D., Wang S., Faltynek C. R., Xie W., Sarup J., Bode D. C., Pagani E. D., Silver P. J. 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular β-type platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 37:1994;2627-2629.
55. Donella-Deana A., Monti E., Pinna L. A. Inhibition of tyrosine protein kinases by the antineoplastic agent adriamycin. Biochem. Biophys. Res. Commun. 160:1989;1309-1315.
56. Dougall W. C., Qian X., Peterson N. C., Miller M. J., Samanta A., Greene M. I. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies Oncogene. 9:1994;2109-2123.
57. Dow R. L. Progress toward selective inhibition of protein kinase C. Curr. Med. Chem. 1:1994;192-203.
58. Dow R. L., Chou T. T., Bechle B. M., Goddard C., Larson E. R. Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine kinase inhibitors. J. Med. Chem. 37:1994;2224-2231.
59. Drebin J. A., Link V. C., Stern D. F., Weinberg R. A., Greene M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell. 41:1985;695-706.
60. lck. Nature. 362:1993;87-91.
61. Erpel T., Courtneidge S. A. Src family protein tyrosine kinases and cellular signal transduction pathways. Curr. Opin. Cell Biol. 7:1995;176-182.
62. lck tyrosine kinase activity. Biochemistry. 34:1995;12404-12410. a.
63. lck tyrosine kinase inhibitor. J. Enzym. Inhib. 9:1995;111-122. b.
64. Fantl W. J., Escobedo J. A., Martin G. A., Turck C. W., del Rosario M., McCormick F., Williams L. T. Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell. 69:1992;413-423.
65. Faux M. C., Scott J. D. More on the target with protein phosphorylation: conferring specificity by location Trends Biochem. Sci. 21:1996;312-315.
66. Ferrigni N. R., McLaughlin J. L., Powell R. G., Smith C. R. Jr. Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J. Nat. Prod. 47:1984;347-352.
67. Flückiger-Isler R. E., Walter P. Stimulation of rat liver glycogen synthesis by the adenosine kinase inhibitor 5-iodotubercidin. Biochem. J. 292:1993;85-89.
68. Fredenhagen A., Mett H., Meyer T., Buchdunger E., Regenass U., Roggo B. E., Petersen F. Protein tyrosine kinase and protein kinase C inhibition by fungal anthraquinones related to emodin. J. Antibiot. (Tokyo). 48:1995;1355-1358.
69. Fry D. W. Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors. Exp. Opin. Invest. Drugs. 3:1994;577-595.
70. Fry D. W., Bridges A. J. Inhibitors of protein tyrosine kinases. Curr. Opin. Biotechnol. 6:1995;662-667.
71. Fry D. W., Nelson J. M. Inhibition of basic fibroblast growth factor-mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors. Anticancer Drug Des. 10:1995;607-622.
72. Fry D. W., Kraker A. J., Connors R. C., Elliott W. L., Nelson J. M., Showalter H. D., Leopold W. R. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anticancer Drug Des. 9:1994;331-351. a.
73. Fry D. W., Kraker A. J., McMichael A., Ambroso L. A., Nelson J. M., Leopold W. R., Connors R. W., Bridges A. J. A specific inhibitor of the epidermal growth factor receptor. Science. 265:1994;1093-1095. b.
74. Fry D. W., McMichael A., Singh J., Dobrusin E. M., McNamara D. J. Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phosphorylation sites of phospholipase C-γ 1. Peptides. 15:1994;951-957. c.
75. Fu X., Schmitz F. J., Lee R. H., Papkoff J. S., Slate D. L. Inhibitors of protein tyrosine kinase 60v-src sterol sulfates from the brittle star Ophiarachna incrassata. J. Nat. Prod. 57:1994;1591-1594.
76. v-src kinase activity in vitro. Biochem. Biophys. Res. Commun. 173:1990;276-282.
77. Fukazawa H., Li P. M., Yamamoto C., Murakami Y., Mizuno S., Uehara Y. Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro. Biochem. Pharmacol. 42:1991;1661-1671.
78. 14C]herbimycin A and its use in the elucidation of the kinase inactivation mechanism. FEBS Lett. 340:1994;155-158.
79. Gazit A., Yaish P., Gilon C., Levitzki A. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors J. Med. Chem. 32:1989;2344-2352.
80. Gazit A., Osherov N., Posner I., Yaish P., Poradosu E., Gilon C., Levitzki A. Tyrphostins: 2. Heterocyclic and α-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of the EGF receptor and ErbB2/Neu tyrosine kinases J. Med. Chem. 34:1991;1896-1907.
81. Gazit A., Osherov N., Posner I., Bar-Sinai A., Gilon C., Levitzki A. Tyrphostins: 3. Structure-activity relationship studies of α-substituted benzylidenemalononitrile 5-S-aryltyrphostins J. Med. Chem. 36:1993;3556-3564.
82. Gazit A., App H., McMahon G., Chan J., Levitzki A., Bohmer F. D. Tyrphostins: 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure activity relationships of quinoxalines, quinolines, and indole tyrphostins J. Med. Chem. 39:1996;2170-2177. a.
83. Gazit A., Osherov N., Gilon C., Levitzki A. Tyrphostins: 6. Dimeric benzylidenemalononitrile tyrphostins: potent inhibitors of the EGF receptor tyrosine kinase in vitro J. Med. Chem. 39:1996;4905-4911. b.
84. Geahlen R. L., McLaughlin J. L. Piceatannol (3,4,3′,5′-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem. Biophys. Res. Commun. 165:1989;241-245.
85. Geissler J. F., Roesel J. L., Meyer J. L., Trinks U. P., Traxler P., Lydon N. B. Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-Abl kinase Cancer Res. 52:1992;4492-4498.
86. Gilmer T., Rodriguez M., Jordan S., Crosby R., Alligood K., Green M., Kimery M., Wagner C., Kinder D., Charifson P., Hassell A., Willard D., Luther M., Rusnak D., Sternbach D., Mehrotra M., Peel M., Shampine L., Davis R., Robbins J., Patel I. R., Kassel D., Burkhart W., Moyer M., Bradshaw T., Berman J. Peptide inhibitors of src SH3-SH2-phosphoprotein interactions. J. Biol. Chem. 269:1994;31711-31719.
87. Glass D. B., Cheng H. C., Mende-Mueller L., Reed J., Walsh D. A. Primary structural determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein. J. Biol. Chem. 264:1989;8802-8810.
88. src.(Naunyn Schmiedebergs Arch. Pharmacol. 317):1981;100-102.
89. Govindan M., Abbas S. A., Schmitz F. J., Lee R. H., Papkoff J. S., Slate D. L. New cycloartanol sulfates from the alga Tydemania expeditionis: inhibitors of the protein tyrosine kinase 60v-src J. Nat. Prod. 57:1994;74-78
90. Graziani Y., Erikson E., Erickson R. L. The effect of quercetin on the phosphorylation of the Rous sarcoma virus transforming gene product in vitro and in vivo. Eur. J. Biochem. 135:1983;583-589.
91. Hagiwara M., Inoue S., Tanaka T., Nunoki K., Ito M., Hidaka H. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Biochem. Pharmacol. 37:1988;2987-2992.
92. Hanke J. H., Gardner J. P., Dow R. L., Changelian P. S., Brissette W. H., Weringer E. J., Pollok B. A., Connelly P. A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor: study of Lck- and FynT-dependent T cell activation J. Biol. Chem. 271:1996;695-701.
93. Hanks S. K., Quinn A. M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains Science. 241:1988;42-52.
94. Harlan J. E., Hajduk P. J., Yoon H. S., Fesik S. W. Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate. Nature. 371:1994;168-170.
95. Harlan J. E., Yoon H. S., Hajduk P. J., Fesik S. W. Structural characterization of the interaction between a pleckstrin homology domain and phosphatidylinositol 4,5-bisphosphate. Biochemistry. 34:1995;9859-9864.
96. Hidaka H., Kobayashi R. Protein kinase inhibitors. Essays Biochem. 28:1994;73-97.
97. Hsu C.-Y., Persons P. E., Spada A. P., Bednar R. A., Levitzki A., Zilberstein A. Kinetic analysis of the inhibition of the epidermal growth factor receptor tyrosine kinase by lavendustin A and its analog. J. Biol. Chem. 266:1991;21105-21112.
98. Hsu C.-Y., Jakowski M. V., Maguire M. P., Spada A. P., Zilberstein A. Inhibition kinetics and selectivity of the tyrosine kinase inhibitor erbstatin and a pyridone-based analog. Biochem. Pharmacol. 43:1992;2471-2477.
99. Huang H. C., Lai M. W., Wang H. R., Chung Y. L., Hsieh L. M., Chen C. C. Antiproliferative effect of esculetin on vascular smooth muscle cells: possible roles of signal transduction pathways Eur. J. Pharmacol. 237:1993;39-44.
100. Hunter T. 1001 protein kinases redux - towards 2000. Semin. Cell Biol. 5:1994;367-376.
101. Hynes N. E., Stern D. F. The biology of ErbB-2/Neu/HER-2 and its role in cancer. Biochim. Biophys. Acta. 1198:1994;165-184.
102. Imoto M. K., Umezawa K., Isshiki K., Kunimoto S., Sawa T., Takeuchi T., Umezawa H. Kinetic studies of tyrosine kinase inhibitors by erbstatin. J. Antibiot. (Tokyo). 40:1987;1471-1473.
103. Jacquemin-Sablon A., Agbotounou W. K., Pierre J. Les inhibiteurs de proteine-tyrosine kinases: perspectives pharmacologiques? Pathol. Biol. (Paris). 43:1995;389-394.
104. Jayasuriya H., Koonchanok N. M., Geahlen R. L., McLaughlin J. L., Chang C. J. Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum. J. Nat. Prod. 55:1992;696-698.
105. Jayatilake G. S., Jayasuriya H., Lee E.-S., Koonchanok N. M., Geahlen R. L., Ashendel C. L., McLaughlin J. L., Chang C.-J. Kinase inhibitors from Polygonum cuspidatum. J. Nat. Prod. 56:1993;1805-1810.
106. Johnson J. A., Gray M. O., Chen C. H., Mochly-Rosen D. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. J. Biol. Chem. 271:1996;24,962-24,966.
107. June C. H., Fletcher M. C., Ledbetter J. A., Schieven G. L., Siegel J. N., Phillips A. F., Samelson L. E. Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 87:1990;7722-7726.
108. Kashiwada Y., Huang L., Ballas L. M., Jiang J. B., Janzen W. P., Lee K. H. New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C. J. Med. Chem. 37:1994;195-200.
109. Kaur G., Gazit A., Levitzki A., Stowe E., Cooney D. A., Sausville E. A. Tyrphostin induced growth inhibition: correlation with effect on p210Bcr-Abl autokinase activity in K562 chronic myelogenous leukemia Anticancer Drugs. 5:1994;213-222.
110. Kavanaugh W. M., Williams L. T. An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. Science. 266:1994;1862-1865.
111. Kim M. H., Lai J. H., Hangauer D. G. Tetrapeptide tyrosine kinase inhibitors: enantioselective synthesis of p-hydroxymethyl-L-phenylalanine, incorporation into a tetrapeptide, and subsequent elaboration into p-(R,S-hydroxyphosphonomethyl)-L-phenylalanine. Int. J. Pept. Protein Res. 44:1994;457-465.
112. Kovalenko M., Gazit A., Bohmer A., Rorsman C., Ronnstrand L., Heldin C. H., Waltenberger J., Bohmer F. D., Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse Sis-transformation. Cancer Res. 54:1994;6106-6114.
113. Kraker A. J., Jones J. A., Schemmel M. E., Moore C. W. Inhibition of epidermal growth factor receptor tyrosine kinases by 2-thioindoles: a new structural class of tyrosine class inhibitor Proc. Am. Assoc. Cancer Res. 34:1993;408.
114. Kraker A. J., Schemmel M. E., Poulter C. J., Moore C. W. Mechanism of inhibition of epidermal growth factor tyrosine kinases by indolene-2-thione and indoline-2-selenone dimers. Proc. Am. Assoc. Cancer Res. 35:1994;443.
115. Kruse C. H., Holden K. G., Offen P. H., Pritchard M. L., Feild J. A., Rieman D. J., Bender P. E., Ferguson B., Greig R. G., Poste G. Synthesis and evaluation of multisubstrate inhibitors of an oncogene-encoded tyrosine-specific protein kinase: 2 J. Med. Chem. 31:1988;1768-1772. a.
116. Kruse C. H., Holden K. G., Pritchard M. L., Feild J. A., Rieman D. J., Greig R. G., Poste G. Synthesis and evaluation of multisubstrate inhibitors of an oncogene-encoded tyrosine-specific protein kinase: 1 J. Med. Chem. 31:1988;1762-1767. b.
117. Kunkel M. W., Hook K. E., Howard C. T., Przybranowski S., Roberts B. J., Elliott W. L., Leopold W. R. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest. New Drugs. 13:1996;295-302.
118. Kwon H. J., Yoshida M., Fukui Y., Horinouchi S., Beppu T. Potent and specific inhibition of 60v-Src protein kinase both in vivo and in vitro by radicicol. Cancer Res. 52:1992;6926-6930.
119. Kwon Y. G., Mendelow M., Srinivasan J., Lee T. R., Pluskey S., Salerno A., Lawrence D. S. The active site substrate specificity of the cAMP-dependent protein kinase. J. Biol. Chem. 268:1993;10713-10716. a.
120. Kwon Y. G., Srinivasan J., Mendelow M., Pluskey S., Lawrence D. S. Stereochemistry specifies the regiochemistry of phosphorylation in two cAMP-dependent protein kinase substrates. J. Biol. Chem. 268:1993;16725-16729. b.
121. Kwon Y. G., Srinivasan J., Mendelow M., Pluskey S., Lawrence D. S. The camp-dependent protein kinase discriminates between prochiral hydroxyl groups. J. Am. Chem. Soc. 115:1993;7527-7528. c.
122. Kwon Y. G., Mendelow M., Lawrence D. S. The active site substrate specificity of protein kinase C. J. Biol. Chem. 269:1994;4839-4844.
123. Ladbury J. E., Lemmon M. A., Zhou M., Green J., Botfield M. C., Schlessinger J. Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal Proc. Natl. Acad. Sci. USA. 92:1995;3199-3203.
124. Langdon S. P., Smyth J. F. Inhibition of cell signalling pathways. Cancer Treat. Rev. 21:1995;65-89.
125. Lee R. H., Slate D. L., Moretti R., Alvi K. A., Crews P. Marine sponge polyketide inhibitors of protein tyrosine kinase. Biochem. Biophys. Res. Commun. 184:1992;765-772.
126. Lee T. R., Mendelow M., Srinivasan J., Kwon Y.-G., Lawrence D. S. The molecular basis for the substrate specificity of a serine/threonine-specific protein kinase. J. Am. Chem. Soc. 115:1993;9888-9891.
127. Lee T. R., Niu J., Lawrence D. S. Phenol kinase activity of the serine/threonine-specific cAMP-dependent protein kinase: steric and electronic effects Biochemistry. 33:1994;4245-4250.
128. Lee T. R., Niu J., Lawrence D. S. The extraordinary active site substrate specificity of 60c-Src a kinase. J. Biol. Chem. 270:1995;5375-5380.
129. Lee T. R., Till J. H., Lawrence D. S., Miller W. T. Precision substrate targeting of protein kinases: v-Abl and c-Src J. Biol. Chem. 270:1995;27022-27026. b.
130. Lemmon M. A., Ferguson K. M., O'Brien R., Sigler P. B., Schlessinger J. Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain. Proc. Natl. Acad. Sci. USA. 92:1995;10472-10476.
131. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development Science. 267:1995;1782-1788.
132. Levitzki A., Gilon C. Tyrphostins as molecular tools and potential antiproliferative drugs. Trends Pharmacol. Sci. 12:1991;171-174.
133. Lewin B. Driving the cell cycle: M phase kinase, its partners and substrates Cell. 61:1990;743-752.
134. Lck. Biochem. Biophys. Res. Commun. 180:1991;1048-1056.
135. Liao L., Hyatt S. L., Chapline C., Jaken S. Protein kinase C domains involved in interactions with other proteins. Biochemistry. 33:1994;1229-1233.
136. Lindberg R. A., Quinn A. M., Hunter T. Dual-specificity protein kinases: will any hydroxyl do? Trends Biochem. Sci. 17:1992;114-119.
137. MacKintosh C., MacKintosh R. W. Inhibitors of protein kinases and phosphatases. Trends Biochem. Sci. 19:1995;444-448.
138. Maguire M. P., Sheets K. R., McVety K., Spada A. P., Zilberstein A. A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives J. Med. Chem. 37:1994;2129-2137.
139. Mahon T. M., O'Neill L. A. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-kappa B activation in T lymphocytes: evidence for covalent modification of the p50 subunit J. Biol. Chem. 270:1995;28557-28564.
140. Src.(J. Biol. Chem. 258):1983;4055-4058.
141. Massillon D., Stalmans W., van de Werve G., Bollen M. Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor. Biochem. J. 299:1994;123-128.
142. McNamara D. J., Dobrusin E. M., Zhu G., Decker S. J., Saltiel A. R. Inhibition of binding of phospholipase Cγ1 SH2 domains to phosphorylated epidermal growth factor receptor by phosphorylated peptides. Int. J. Pept. Protein Res. 42:1993;240-248.
143. lck inhibitors Drug Dev. Res. 34:1995;344-352.
144. Miller P., DiOrio C., Moyer M., Schnur R. C., Bruskin A., Cullen W., Moyer J. D. Depletion of the ErbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res. 54:1994;2724-2730. a.
145. Miller P., Schnur R. C., Barbacci E., Moyer M. P., Moyer J. D. Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the ErbB2 gene product p185. Biochem. Biophys. Res. Commun. 20:1994;1313-1319. b.
146. Million M.-E., Mailliett P., Chen H., Bashiardes G., Boiziau J., Parker F., Commercon A., Tocque B., Roques B. P., Garbay C. Synthesis and biological evaluation of a new series of phenylhydroquinone derivatives as inhibitors of EGF-R-associated PTK activity. Anticancer Drug Des. 11:1996;129-153.
147. c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271:1996;22796-22801.
148. Moarefi I., LaFevre-Bernt M., Sicheri F., Huse M., Lon C.-H., Kuriyan J., Miller W. T. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature. 385:1997;650-653.
149. Mochly-Rosen D. Localization of protein kinases by anchoring proteins: a theme in signal transduction Science. 268:1995;247-251.
150. Muthuswamy S. K., Muller W. J. Activation of the Src family kinases in mammary tumorigenesis. Adv. Cancer Res. 64:1994;111-123.
151. Nair S. A., Kim M. H., Warren S. D., Choi S., Zhou S., Cantley L. C., Hangauer D. G. Identification of efficient pentapeptide substrates for the tyrosine kinase 60c-Src. J. Med. Chem. 38:1995;4276-4283.
152. Nicklaus M. C., Milne G. W., Burke T. R. Jr. QSAR of conformationally flexible molecules: comparative molecular field analysis of protein-tyrosine kinase inhibitors J Comput. Aided Mol. Des. 6:1992;487-504.
153. Niu J., Lawrence D. S. Nonphosphorylatable tyrosine surrogates: implications for protein kinase inhibitor design J. Biol. Chem. 272:1997;1493-1499. a.
154. Niu J., Lawrence D. S. L-Dopa: a potent nonphosphorylatable tyrosine mimetic for 60c-src J. Am. Chem. Soc. 119:1997;3844-3845. b.
155. Nussbaumer P., Winiski A. P., Cammisuli S., Hiestand P., Weckbecker G., Stutz A. Novel antiproliferative agents derived from lavendustin A. J. Med. Chem. 37:1994;4079-4084.
156. Ohmichi M., Pang L., Ribon V., Gazit A., Levitzki A., Salteil A. R. The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor. Biochemistry. 32:1993;4650-4658.
157. Oliver J. M., Burg D. L., Wilson B. S., McLaughlin J. L., Geahlen R. L. Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J. Biol. Chem. 269:1994;29697-29703.
158. Onoda T., Iinuma H., Sasaki Y., Hamada M., Isshiki K., Naganawa H., Takeuchi T., Tatsuta K., Umezawa K. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. J. Nat. Prod. 52:1989;1252-1257.
159. Onoda T., Isshiki K., Takeuchi T., Tatsuta K., Umezawa K. Inhibition of tyrosine kinase and epidermal growth factor receptor internalization by lavendustin A methyl ester in cultured A431 cells. Drugs Exp. Clin. Res. 16:1990;249-253.
160. Osherov N., Gazit A., Gilon C., Levitzki A. Selective inhibition of the epidermal growth factor and HER2/Neu receptors by tyrphostins. J. Biol. Chem. 268:1993;11134-11142.
161. Palmer B. D., Rewcastle G. W., Thompson A. M., Boyd M., Showalter H. D., Sercel A. D., Fry D. W., Kraker A. J., Denny W. A. Tyrosine kinase inhibitors: 4. Structure-activity relationships among N- and 3-substituted 2,2′-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases J. Med. Chem. 38:1995;58-67.
162. Pang S. H., Guo Z. R. Advances in the research on tyrosine protein kinase inhibitors. Acta Pharm. Sin. 31:1996;75-80.
163. Pawson T. SH2 and SH3 domains in signal transduction. Adv. Cancer Res. 64:1994;87-110.
164. Pawson T. Protein modules and signalling networks. Nature. 373:1995;573-580.
165. src Src homology 2 domain binding to tyrosine-phosphorylated peptides determined by a competition assay or surface plasmon resonance. Proc. Natl. Acad. Sci. USA. 90:1993;4902-4906.
166. Pendergast A. M. Nuclear tyrosine kinases: from Ab1 to WEE1 Curr. Opin. Cell Biol. 8:1996;174-186.
167. Philip P. A., Harris A. L. Potential for protein kinase C inhibitors in cancer therapy. Cancer Treat. Res. 78:1995;3-27.
168. Pinna L. A., Ruzzene M. How do protein kinases recognize their substrates? Biochim. Biophys. Acta. 1314:1996;191-225.
169. Pisabarro M. T., Serrano L. Rational design of specific high-affinity peptide ligands for the Abl-SH3 domain. Biochemistry. 35:1996;10634-10640.
170. Pluskey S., Wandless T. J., Walsh C. T., Shoelson S. E. Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. J. Biol. Chem. 270:1995;2897-2900.
171. Posner I., Engel M., Gazit A., Levitzki A. Kinetics of inhibition by tyrphostins of the tyrosine kinase of the epidermal growth factor receptor and analysis by a new computer program. Mol. Pharmacol. 45:1994;673-683.
172. Powis G. Anticancer drugs acting against signaling pathways. Curr. Opin. Oncol. 7:1995;554-559.
173. Powis G., Alberts D. S. Inhibiting intracellular signalling as a strategy for cancer chemoprevention. Eur. J. Cancer. 30A:1994;1138-1144.
174. 3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins. Cell. 83:1995;821-830.
175. Rewcastle G. W., Palmer B. D., Dobrusin E. M., Fry D. W., Kraker A. J., Denny W. A. Tyrosine kinase inhibitors: 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivative of 2,2′-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide) J. Med. Chem. 37:1994;2033-2042.
176. Rewcastle G. W., Denny W. A., Bridges A. J., Zhou H., Cody D. R., McMichael A., Fry D. W. Tyrosine kinase inhibitors: 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor J. Med. Chem. 38:1995;3482-3487.
177. Rewcastle G. W., Palmer B. D., Bridges A. J., Showalter H. D., Sun L., Nelson J., McMichael A., Kraker A. J., Fry D. W., Denny W. A. Tyrosine kinase inhibitors: 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor J. Med. Chem. 39:1996;918-928. a.
178. Rewcastle G. W., Palmer B. D., Thompson A. M., Bridges A. J., Cody D. R., Zhou H., Fry D. W., McMichael A., Denny W. A. Tyrosine kinase inhibitors: 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP-binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor J. Med. Chem. 39:1996;1823-1835. b.
179. Rickles R. J., Botfield M. C., Weng Z., Taylor J. A., Green O. M., Brugge J. S., Zoller M. J. Identification of Src, Fyn, Lyn, PI3K and Abl SH3 domain ligands using phage display libraries. EMBO J. 13:1994;5598-5604.
180. Rickles R. J., Botfield M. C., Zhou X. M., Henry P. A., Brugge J. S., Zoller M. J. Phage display selection of ligand residues important for Src homology 3 domain binding specificity. Proc. Natl. Acad. Sci. USA. 92:1995;10909-10913.
181. Rordorf-Nikolic T., Van Horn D. J., Chen D., White M. F., Backer J. M. Regulation of phosphatidylinositol 3′-kinase by tyrosyl phosphoproteins: full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit J. Biol. Chem. 270:1995;3662-3666.
182. Rowley R. B., Burkhardt A. L., Chao H. G., Matsueda G. R., Bolen J. B. Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation. J. Biol. Chem. 270:1995;11590-11594.
183. Rubin C. S. A kinase anchor proteins and the intracellular targeting of signals carried by cyclic AMP. Biochim. Biophys. Acta. 1224:1994;467-479.
184. Ruzza P., Deana A. D., Calderan A., Pavanetto M., Cesaro L., Pinna L. A., Borin G. Synthetic Tyr-phospho and non-hydrolyzable phosphonopeptides as PTKs and TC-PTP inhibitors. Int. J. Pept. Protein Res. 46:1995;535-546.
185. Sabe H., Hata A., Okada M., Nakagawa H., Hanafusa H. Analysis of the binding of the Src homology 2 domain of Csk to tyrosine-phosphorylated proteins in the suppression and mitotic activation of c-Src. Proc. Natl. Acad. Sci. USA. 91:1994;3984-3988.
186. Schnur R. C., Corman M. L., Gallaschun R. J., Cooper B. A., Dee M. F., Doty J. L., Muzzi M. L., DiOrio C. I., Barbacci E. G., Miller P. E., Pollack V. A., Savage D. M., Sloan D. E., Pustilnik L. R., Moyer J. D., Moyer M. P. ErbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships J. Med. Chem. 38:1995;3813-3820. a.
187. erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem. 38:1995;3806-3812. b.
188. Sefton B. M., Taddie J. A. Role of tyrosine kinases in lymphocyte activation. Curr. Opin. Immunol. 6:1994;372-379.
189. Segel I. H. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems:1975;Wiley-Interscience, New York.
190. Sepp-Lorenzino, L., Ma, Z., Lebwohl, D. E., Vinitsky, A. and Rosen, N. (1995) Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J. Biol. Chem. 270: 16580-16587.
191. Shaw G. The pleckstrin homology domain: an intriguing multifunctional protein module Bioessays. 18:1996;35-46.
192. Shiraishi T., Domoto T., Imai N., Shimada Y., Watanabe K. Specific inhibitors of tyrosine-specific protein kinase, synthetic 4-hydroxycinnamamide derivatives. Biochem. Biophys. Res. Commun. 147:1987;322-328.
193. Shiraishi T., Owada M. K., Tatsuka M., Yamashita T., Watanabe K., Kakunaga T. Specific inhibitors of tyrosine-specific protein kinases: properties of 4-hydroxycinnamamide derivatives in vitro Cancer Res. 49:1989;2374-2378.
194. Shisheva A., Shechter Y. Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. Biochemistry. 31:1992;8059-8063.
195. Shiue L., Zoller M. J., Brugge J. S. Syk is activated by phosphotyrosine-containing peptides representing the tyrosine-based activation motifs of the high affinity receptor for IgE. J. Biol. Chem. 270:1995;10498-10502.
196. Shoelson S. E., White M. F., Kahn C. R. Nonphosphorylatable substrate analogs selectively block autophosphorylation and activation of the insulin receptor, epidermal growth factor receptor, and60v-src kinases. J. Biol. Chem. 264:1989;7831-7836.
197. Shoelson S. E., Sivaraja M., Williams K. P., Hu P., Schlessinger J., Weiss M. A. Specific phosphopeptide binding regulates a conformational change in the PI 3-kinase SH2 domain associated with enzyme activation. EMBO J. 12:1993;795-802.
198. Showalter H. D., Sercel A. D., Borguslawa M. L., Wolfangel C. D., Ambroso L. A., Elliot W. L., Fry D. F., Kraker A. J., Howard C. T., Lu G. H., Moore C. W., Nelson J. M., Roberts B. J., Vincent P. W., Denny W. A., Thompson A. M. Tyrosine kinase inhibitors: 6. Structure-activity relationships among N- and 3-substituted 2,2′-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners J. Med. Chem. 40:1997;413-426.
199. Shugar D. Protein kinase inhibitors: potential chemotherapeutic agents Acta Biochim. Pol. 42:1995;405-418.
200. Sicheri F., Moarefi I., Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature. 385:1997;602-609.
201. Singh J., Dobrusin E. M., Fry D. W., Haske T., Whitty A., McNamara D. J. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the ErbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 40:1997;1130-1135.
202. Slate D. L., Lee R. H., Rodriguez J., Crews P. The marine natural product, halistanol trisulfate, inhibits 60v-src protein tyrosine kinase activity. Biochem. Biophys. Res. Commun. 203:1994;260-264.
203. Smith C. M., Shindyalov I. N., Veretnik S., Gribskov M., Taylor S. S., Ten Eyck L. F., Bourne P. E. The protein kinase resource. Trends. Biochem. Sci. 22:1997;444-446.
204. Smyth M. S., Stefanova I., Hartmann F., Horak I. D., Osherov N., Levitzki A., Burke T. R. Jr. Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors. J. Med. Chem. 36:1993;3010-3014. a.
205. Smyth M. S., Stefanova I., Horak I. D., Burke T. R. Jr. Hydroxylated 2-(5′-salicyl)naphthalenes as protein-tyrosine kinase inhibitors. J. Med. Chem. 36:1993;3015-3020. b.
206. Songyang Z., Shoelson S. E., Chaudhuri M., Gish G., Pawson T., Haser W. G., King F., Roberts T., Ratnofsky S., Lechleider R. J., Lechleider R. J., Neel B. G., Birge R. B., Fajardo J. E., Chou M. M., Hanafusa H., Schafhausen B., Cantley L. C. SH2 domains recognize specific phosphopeptide sequences. Cell. 72:1993;767-778.
207. Songyang Z., Margolis B., Chaudhuri M., Shoelson S. E., Cantley L. C. The phosphotyrosine interaction domain of SHC recognized tyrosine-phosphorylated NPXY motif. J. Biol. Chem. 270:1995;14863-14866.
208. Sparks A. B., Quilliam L. A., Thorn J. M., Der C. J., Kay B. K. Identification and characterization of Src SH3 ligands from phage-displayed random peptide libraries. J. Biol. Chem. 269:1994;23853-23856.
209. Sparks A. B., Adey N. B., Quilliam L. A., Thorn J. M., Kay B. K. Screening phage-displayed random peptide libraries for SH3 ligands. Methods Enzymol. 255:1995;498-509.
210. Sparks A. B., Rider J. E., Hoffman N. G., Fowlkes D. M., Quillam L. A., Kay B. K. Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLCγ, Crk, and Grb2. Proc. Natl. Acad. Sci. USA. 93:1996;1540-1544.
211. Staudinger J., Zhou J., Burgess R., Elledge S. J., Olson E. N. PICK1: a perinuclear binding protein and substrate for protein kinase C isolated by the yeast two-hybrid system J. Cell Biol. 128:1995;263-271.
212. Sun X. J., Wang L.-M., Zhang Y., Yenush L., Myers M. G., Glasheen E., Lane W. S., Pierce J. H., White M. F. Role of IRS-2 in insulin and cytokine signalling. Nature. 377:1995;173-177.
213. Tanaka S., Okabe T., Chieda S., Endo K., Kanoh T., Okura A., Yoshida E. BE-23372M, a novel and specific inhibitor for the epidermal growth factor receptor kinase. Jpn. J. Cancer Res. 85:1994;253-259.
214. Taylor S. J., Shalloway D. Src and the control of cell division. Bioessays. 18:1996;9-11.
215. Thakkar K., Geahlen R. L., Cushman M. Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol. J. Med. Chem. 36:1993;2950-2955.
216. lck to the activated T cell receptor/CD3/zeta complex. Eur. J. Immunol. 26:1996;2093-2100.
217. Thompson A. M., Rewcastle G. W., Tercel M., Dobrusin E. M., Fry D. W., Kraker A. J., Denny W. A. Tyrosine kinase inhibitors: 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2′-dithiobis(1H-indole-3-alkanoic acids) J. Med. Chem. 36:1993;2459-2469.
218. v-src protein tyrosine kinases J. Med. Chem. 37:1994;598-609.
219. Thompson A. M., Bridges A. J., Fry D. W., Kraker A. J., Denny W. A. Tyrosine kinase inhibitors: 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido [4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor J. Med. Chem. 38:1995;3780-3788.
220. Traut T. W. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140:1994;1-22.
221. Traxler P. M., Wacker O., Bach H. L., Geissler J. F., Kump W., Meyer T., Regenass U., Roesel J. L., Lydon N. Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase J. Med. Chem. 34:1991;2328-2337.
222. Traxler P. M., Furet P., Mett H., Buchdunger E., Meyer T., Lydon N. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase J. Med. Chem. 39:1996;2285-2292.
223. Trinks U., Buchdunger E., Furet P., Kump W., Mett H., Meyer T., Muller M., Regenass U., Rihs G., Lydon N., Traxler P. Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase J. Med. Chem. 37:1994;1015-1027.
224. Uehara Y., Fukazawa H., Murakami Y., Mizuno S. Irreversible inhibition of v-Src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem. Biophys. Res. Commun. 163:1989;803-809. a.
225. v-Src1 Cancer Res. 49:1989;780-785. b.
226. Umezawa H., Imoto M., Sawar T., Issihiki K., Matsuda N., Uchida T., Finuma H., Hamada M., Takeuchi T. Studies on a new epidermal growth factor kinase inhibitor, erbstatin, produced by MH435-hF3. J. Antibiot. (Tokyo). 39:1986;170-173.
227. van der Geer P., Pawson T. The PTB domain: a new protein module implicated in signal transduction Trends Biochem. Sci. 20:1995;277-280.
228. Wang Z., Moran M. F. Requirement for the adapter protein GRB2 in EGF receptor endocytosis. Science. 272:1996;1935-1939.
229. 3, a novel competitive inhibitor of the binding of ZAP-70 to the T cell antigen receptor, blocks early T cell signaling. J. Biol. Chem. 270:1995;944-948.
230. Ward W. H. J., Cook P. N., Slater A. M., Davies D. H., Holdgate G. A., Green L. R. Epidermal growth factor receptor tyrosine kinase: investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor Biochem. Pharmacol. 48:1994;659-666.
231. Whitesell L., Mimnaugh E. G., De Costa B., Myers C. E., Neckers L. M. Inhibition of heat shock protein HSP90-pp60v-Src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation Proc. Natl. Acad. Sci. USA. 91:1994;8324-8328.
232. Wong T. W., Goldberg A. R. Kinetics and mechanism of angiotensin phosphorylation by the transforming gene product of Rous sarcoma virus. J. Biol. Chem. 259:1984;3127-3131.
233. Wood J. S., Yan X., Mendelow M., Corbin J. D., Francis S. H., Lawrence D. S. Precision substrate targeting of protein kinases: the cGMP- and cAMP-dependent protein kinases J. Biol. Chem. 271:1996;174-179.
234. Xu W., Harrison S. C., Eck M. J. Three-dimensional structure of the tyrosine kinase c-Src. Nature. 385:1997;595-601.
235. Yaish P., Gazit A., Gilon C., Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science. 242:1988;933-935.
236. Yan X., Lawrence D. S., Corbin J. D., Francis S. H. Distinguishing between a mitogenic and two closely related nonmitogenic protein kinases. J. Am. Chem. Soc. 118:1996;11684-11685.
237. Ye B., Akamatsu M., Shoelson S. E., Wolf G., Giorgetti-Peraldi S., Yan X., Roller P. P., Burke T. R. Jr. L-O-(2-Malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides J. Med. Chem. 38:1995;4270-4275.
238. Yedovitzky M., Mochly-Rosen D., Johnson J. A., Gray M. O., Ron D., Abramovitch E., Cerasi E., Nesher R. Translocation inhibitors define specificity of protein kinase C isoenzymes in pancreatic β-cells. J. Biol. Chem. 272:1997;1417-1420.
239. Young S. W., Poole R. C., Hudson A. T., Halestrap A. P., Denton R. M., Tavaré J. M. Effects of tyrosine kinase inhibitors on protein kinase-independent systems. FEBS Lett. 316:1993;278-282.
240. Yuan C. J., Jakes S., Elliott S., Graves D. J. A rationale for the design of an inhibitor of tyrosyl kinase. J. Biol. Chem. 265:1990;16205-16209.